(Q37649477)

21 August 2017

1 reference

title

Innovations in the systemic therapy of prostate cancer (English)

1 reference

21 August 2017

1 reference

1 reference

Dale R Shepard

1

1 reference

21 August 2017

Derek Raghavan

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

8 December 2009

1 reference

Nature Reviews Clinical Oncology

21 August 2017

published in

1 reference

21 August 2017

volume

7

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

13-21

1 reference

Immunotherapy for metastatic prostate cancer

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for hi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Ketoconazole therapy for advanced prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Advances in specific immunotherapy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Role of secondary hormonal therapy in the management of recurrent prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Increased metastatic lymph node 64 and CYP17 expression are associated with high stage prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

The androgen axis in recurrent prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Cancer treatment-induced bone loss in breast and prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Functional heterogeneity of prostatic intraepithelial neoplasia: the duration of hormonal therapy influences the response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Changing patterns in competing causes of death in men with prostate cancer: a population based study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Long-term effects of androgen deprivation therapy in prostate cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Insulin sensitivity during combined androgen blockade for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Cause of death in men diagnosed with prostate carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Mechanisms of Disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.187

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

31 March 2020

1 reference

12 December 2020

Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer

1 reference

12 December 2020

A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer

1 reference

12 December 2020

Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results

1 reference

12 December 2020

10.1038/NRCLINONC.2009.187

Identifiers

DOI

1 reference

21 August 2017

1 reference